日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A review of clinical trials registered in India from 2008 to 2022 to describe the first-in-human trials

本文回顾了2008年至2022年间在印度注册的临床试验,旨在描述首次人体试验。

Sabu, Sowparnika Treasa; Venkatraman, Shravan; Cherian, Jerin Jose; Das, Saibal; Pahuja, Monika; Adhikari, Tulsi; Mukherjee, Shoibal; Chatterjee, Nabendu Sekhar; Kshirsagar, Nilima Arun

Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial

0.05% 胶束纳米颗粒 (MNP) 环孢素眼用乳剂治疗中重度干性角结膜炎的疗效和安全性:一项为期 12 周的多中心、随机、阳性对照试验

Rao, A Tarakeswara; Gupta, Amit; Chauhan, Tulika; Basu, Sayan; Batra, Nitin; Sharma, Namrata; Sangwan, Virender S; Gupta, Vinay; Mukherjee, Shoibal

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy

纳他珠单抗相关进行性多灶性白质脑病生存和功能结局的预测因素

Dong-Si, Tuan; Gheuens, Sarah; Gangadharan, Amy; Wenten, Made; Philip, Jeffrey; McIninch, James; Datta, Shoibal; Richert, Nancy; Bozic, Carmen; Bloomgren, Gary; Richman, Sandra; Weber, Thomas; Clifford, David B

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

接受那他珠单抗治疗的多发性硬化症患者中无症状进行性多灶性白质脑病的预后和生存情况

Dong-Si, Tuan; Richman, Sandra; Wattjes, Mike P; Wenten, Made; Gheuens, Sarah; Philip, Jeffrey; Datta, Shoibal; McIninch, James; Bozic, Carmen; Bloomgren, Gary; Richert, Nancy

Pharmacovigilance Symposium ISCR Annual Conference Jan 5, 2013: Safety aspects of hard endpoint or outcome trials

2013年1月5日ISCR年会药物警戒研讨会:硬终点或结果试验的安全性问题

Suvarna, Viraj; Nambiar, Indu; Mukherjee, Shoibal; Mallath, Mohandas K

Sharing global CO2 emission reductions among one billion high emitters

在十亿高排放国之间共享全球二氧化碳减排量

Chakravarty, Shoibal; Chikkatur, Ananth; de Coninck, Heleen; Pacala, Stephen; Socolow, Robert; Tavoni, Massimo